SONN Projected Dividend Yield
Com Par $0.0001/Sonnet BioTherapeutics Holdings Inc ( NASDAQ : SONN )Sonnet BioTherapeutics Holdings is a clinical-stage biopharmaceutical company with a proprietary technology for developing biologic medicines it refers to as FHAB (Fully Human Albumin Binding). Co. has a pipeline of therapeutic compounds focused primarily on oncology indications of unmet medical need, including SON-080, a low-dose formulation of Interleukin 6 which is in development for Chemotherapy Induced Peripheral Neuropathy; SON-1010, which is being developed for solid tumor indications, including non-small cell lung cancer and head and neck cancer, as well as for antiviral applications; and SON-1210, which is being developed for solid tumor indications, including colorectal cancer. 20 YEAR PERFORMANCE RESULTS |
SONN Dividend History Detail SONN Dividend News SONN Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |